Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc (COCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,646
  • Shares Outstanding, K 13,784
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,500 K
  • EBIT $ -10 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.68
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings $-0.19 on 11/14/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.18
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +43.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9009 +11.00%
on 11/24/25
1.1000 -9.09%
on 12/10/25
+0.0988 (+10.96%)
since 11/21/25
3-Month
0.9000 +11.11%
on 11/21/25
1.4150 -29.33%
on 09/23/25
-0.3000 (-23.08%)
since 09/22/25
52-Week
0.9000 +11.11%
on 11/21/25
3.2600 -69.33%
on 12/30/24
-1.2500 (-55.56%)
since 12/20/24

Most Recent Stories

More News
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference

BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $ 1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR)...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE)...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE)...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused...

COCP : 1.0000 (+1.01%)
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company...

COCP : 1.0000 (+1.01%)

Business Summary

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise...

See More

Key Turning Points

3rd Resistance Point 1.0867
2nd Resistance Point 1.0633
1st Resistance Point 1.0267
Last Price 1.0000
1st Support Level 0.9667
2nd Support Level 0.9433
3rd Support Level 0.9067

See More

52-Week High 3.2600
Fibonacci 61.8% 2.3585
Fibonacci 50% 2.0800
Fibonacci 38.2% 1.8015
Last Price 1.0000
52-Week Low 0.9000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar